You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here

ClinicalTrial.gov Identifier : NCT00799877

Chronic Plaque Psoriasis (Ps) Registry

    Status Active, not recruiting
    Related Conditions

Enrollment Details

6082 Worldwide Enrollment Goal

Phases: 

  • 1
  • 2
  • 3
  • 4
Study Type:  Observational

This is a type IV phase trial.

Protocol ID
P10-023

Brief summary

Top

The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).

Participant Attributes :
  • Male and Female
  • Ages 18 Years to 99 Years

Canada: 26

0
Edmonton, AB
1
Edmonton, AB
2
Surrey, BC
3
Vancouver, BC
4
Winnipeg, MB
5
Moncton, NB
6
St. John's, NL
7
St. John's, NL
8
St. John's, NL
9
St. John's, NL
10
Halifax, NS
11
Hamilton, ON
12
London, ON
13
Markham, ON
14
Newmarket, ON
15
Niagara Falls, ON
16
North Bay, ON
17
Peterborough, ON
18
Toronto, ON
19
Waterloo, ON
20
Windsor, ON
21
Drummondville, QC
22
Montreal, QC
23
Quebec, QC
24
Quebec, QC
25
Westmount, QC
Would you like to know more about this trial?

Study Design

  • The relationship between the observation period and the time of patient enrollment. Time perspective can be prospective: looking forward using periodic observations usually collected following patient enrollment, or retrospective: looking back using observations usually collected prior to patient selection and enrollment.
    ?

    Time Perspective

    Prospective

    • An adult patient (18 years of age or older) with chronic plaque psoriasis who has been prescribed HUMIRA® therapy according to the local product labeling and meets one of the following criteria:
      • New initiated (within 4 weeks of registry entry) on HUMIRA® therapy
      • Initiated HUMIRA® therapy in the past and:
        • Has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy and the physician can provide source documentation of SAEs, AEs, of Special Interest, and dosing information since initiation of therapy. OR
      • Is entering after participation in an AbbVie HUMIRA (adalimumab) sponsored study and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy after the completion of AbbVie sponsored study and physician can provide source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of commercial HUMIRA® (defined as a prescribed/non study drug).
    • Patient is willing to consent to data being collected and provided to AbbVie
    • Patient is capable of and willing to give written informed consent and to comply with the requirements of the registry.
    • Patient should not be enrolled if he/she cannot be treated in accordance with the local product label.

More on this trial

Clinical Trials.gov